Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development

References

• Dahan A Lennernäs H Amidon GL The fraction dose absorbed, in humans, and high jejunal human permeability relationship Mol Pharm 2012 9 6 1847 1851 22524707
   PubMed Web of Science ®Google Scholar
• Lennernäs H Abrahamsson B The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension J Pharm Pharmacol 2005 57 3 273 285 15807982
   PubMed Web of Science ®Google Scholar
• Amidon GL Lennernäs H Shah VP Crison JR A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res 1995 12 3 413 420 7617530
   PubMed Web of Science ®Google Scholar
• Amidon KS Langguth P Lennernäs H Yu LX Amidon GL Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy Clin Pharmacol Ther 2011 90 3 467 470 21775984
   PubMed Web of Science ®Google Scholar
• Dahan A Miller JM Amidon GL Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs AAPS J 2009 11 4 740 746 19876745
   PubMed Web of Science ®Google Scholar
• Löbenberg R Amidon GL Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards Eur J Pharm Biopharm 2000 50 1 3 12 10840189
   PubMed Web of Science ®Google Scholar
• Martinez MN Amidon GL A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals J Clin Pharmacol 2002 42 6 620 643 12043951
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research, US Food and Drug Administration Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Rockville (MD) FDA 2000
   Google Scholar
• Yu LX Amidon G Polli J Biopharmaceutics classification system: the scientific basis for biowaiver extensions Pharm Res 2002 19 7 921 925 12180542
   PubMed Web of Science ®Google Scholar
• Cook J Addicks W Wu Y Application of the biopharmaceutical classification system in clinical drug development–an industrial view AAPS J 2008 10 2 306 310 18500563
   PubMed Web of Science ®Google Scholar
• Ku MS Use of the biopharmaceutical classification system in early drug development AAPS J 2008 10 1 208 212 18446521
   PubMed Web of Science ®Google Scholar
• Pham–The H Garrigues T Bermejo M González–Álvarez I Monteagudo MC Cabrera–Pérez MÁ Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number Mol Pharm 2013 10 6 2445 2461 23675957
   PubMed Web of Science ®Google Scholar
• Dahan A Wolk O Kim YH Purely in silico BCS classification: science based quality standards for the world’s drugs Mol Pharm 2013 10 11 4378 4390 24094040
   PubMed Web of Science ®Google Scholar
• Lennernäs H Aarons L Augustijns P Oral biopharmaceutics tools – time for a new initiative – an introduction to the IMI project OrBiTo Eur J Pharm Sci 2014 16 57 292 299 24189462
   PubMed Web of Science ®Google Scholar
• Fairstein M Swissa R Dahan A Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine AAPS J 2013 15 2 589 597 23440549
   PubMed Web of Science ®Google Scholar
• Miller JM Beig A Carr RA Spence JK Dahan A A win–win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability Mol Pharm 2012 9 7 2009 2016 22632106
   PubMed Web of Science ®Google Scholar
• Miller JM Beig A Carr RA Webster GK Dahan A The solubility–permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations Mol Pharm 2012 9 3 581 590 22280478
   PubMed Web of Science ®Google Scholar
• Miller JM Dahan A Predicting the solubility–permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation Int J Pharm 2012 430 1–2 388 391 22465550
   PubMed Web of Science ®Google Scholar
• Lennernäs H Human intestinal permeability J Pharm Sci 1998 87 4 403 410 9548891
   PubMed Web of Science ®Google Scholar
• Lennernäs H Regional intestinal drug permeation: biopharmaceutics and drug development Eur J Pharm Sci 2014 16 57 333 341 23988845
   PubMed Web of Science ®Google Scholar
• Lennernäs H Human in vivo regional intestinal permeability: importance for pharmaceutical drug development Mol Pharm 2014 11 1 12 23 24206063
   PubMed Web of Science ®Google Scholar
• Dahan A Amidon GL MRP2 mediated drug–drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting Int J Pharm 2010 386 1–2 216 220 19944137
   PubMed Web of Science ®Google Scholar
• Dahan A Sabit H Amidon GL The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport AAPS J 2009 11 2 205 213 19319690
   PubMed Web of Science ®Google Scholar
• Dahan A Sabit H Amidon GL Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of P-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine Drug Metab Dispos 2009 37 10 2028 2036 19589874
   PubMed Web of Science ®Google Scholar
• Miller JM Dahan A Gupta D Varghese S Amidon GL Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir Mol Pharm 2010 7 4 1223 1234 20536260
   PubMed Web of Science ®Google Scholar
• Lipinski CA Drug-like properties and the causes of poor solubility and poor permeability J Pharmacol Toxicol Methods 2000 44 1 235 249 11274893
   PubMed Web of Science ®Google Scholar
• Lipinski CA Lombardo F Dominy BW Feeney PJ Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 2001 46 1–3 3 26 11259830
   PubMed Web of Science ®Google Scholar
• Winiwarter S Ax F Lennernäs H Hallberg A Pettersson C Karlén A Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability J Mol Graph Model 2003 21 4 273 287 12479927
   PubMed Web of Science ®Google Scholar
• Benet LZ Broccatelli F Oprea TI BDDCS applied to over 900 drugs AAPS J 2011 13 4 519 547 21818695
   PubMed Web of Science ®Google Scholar
• Hansch C Leo AJ Substituent Constants for Correlation Analysis in Chemistry and Biology New York Wiley 1979
   Google Scholar
• Leo AJ Calculating log Poct from structures Chemical Reviews 1993 93 4 1281 1306
   Web of Science ®Google Scholar
• O’Neil MJ The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals 13th ed Rahway (NJ) Merck 2001
   Google Scholar
• Ghose AK Crippen GM Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions J Chem Inf Comput Sci 1987 27 1 21 35 3558506
   PubMedGoogle Scholar
• Wildman SA Crippen GM Prediction of physicochemical parameters by atomic contributions J Chem Inf Comput Sci 1999 39 5 868 873
   Google Scholar
• Lennernäs H Intestinal permeability and its relevance for absorption and elimination Xenobiotica 2007 37 10–11 1015 1051 17968735
   PubMed Web of Science ®Google Scholar
• Dahan A Miller JM Hilfinger JM High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations Mol Pharm 2010 7 5 1827 1834 20701326
   PubMed Web of Science ®Google Scholar
• Regardh CG Borg KO Johansson R Johnsson G Palmer L Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man J Pharmacokinet Biopharm 1974 2 4 347 364 4155762
   PubMedGoogle Scholar
• Zur M Gasparini M Wolk O Amidon GL Dahan A The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol Mol Pharm 2014 11 5 1707 1714 24735251
   PubMed Web of Science ®Google Scholar
• Klasco RK USP DI^® Drug Information for the Health Care Professional Greenwood Village (CO) Thomson Micromedex 2004
   Google Scholar
• Amidon GL Williams NA A solubility equation for non-electrolytes in water International Journal of Pharmaceutics 1982 11 3 249 256
   Web of Science ®Google Scholar
• Chu XY Bleasby K Yabut J Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein J Pharmacol Exp Ther 2007 321 2 673 683 17314201
   PubMed Web of Science ®Google Scholar
• Ganapathy ME Brandsch M Prasad PD Ganapathy V Leibach FH Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2 J Biol Chem 1995 270 43 25672 25677 7592745
   PubMed Web of Science ®Google Scholar
• Han HK Rhie JK Oh DM CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs J Pharm Sci 1999 88 3 347 350 10052994
   PubMed Web of Science ®Google Scholar
• Kanai Y Endou H Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity J Toxicol Sci 2003 28 1 1 17 12696180
   PubMedGoogle Scholar
• Friedman DI Amidon GL Oral absorption of peptides: influence of pH and inhibitors on the intestinal hydrolysis of leu-enkephalin and analogues Pharm Res 1991 8 1 93 96 2014216
   PubMed Web of Science ®Google Scholar
• Amidon GL Chang M Fleisher D Allen R Intestinal absorption of amino acid derivatives: importance of the free alpha-amino group J Pharm Sci 1982 71 10 1138 1141 7143212
   PubMed Web of Science ®Google Scholar
• Dahan A Khamis M Agbaria R Karaman R Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach Expert Opin Drug Deliv 2012 9 8 1001 1013 22703376
   PubMed Web of Science ®Google Scholar
• Yang B Hu Y Smith DE Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice Drug Metab Dispos 2013 41 10 1867 1874 23924683
   PubMed Web of Science ®Google Scholar
• Yang B Smith DE Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice Drug Metab Dispos 2013 41 3 608 614 23264448
   PubMed Web of Science ®Google Scholar
• Soldner A Benet LZ Mutschler E Christians U Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers Br J Pharmacol 2000 129 6 1235 1243 10725273
   PubMed Web of Science ®Google Scholar
• Weiss J Sauer A Divac N Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters Biopharm Drug Dispos 2010 31 2–3 150 161 20222053
   PubMed Web of Science ®Google Scholar
• Broccatelli F Cruciani G Benet LZ Oprea TI BDDCS class prediction for new molecular entities Mol Pharm 2012 9 3 570 580 22224483
   PubMed Web of Science ®Google Scholar
• Incecayir T Tsume Y Amidon GL Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification Mol Pharm 2013 10 3 958 966 23327720
   PubMed Web of Science ®Google Scholar
• Kasim NA Whitehouse M Ramachandran C Molecular properties of WHO essential drugs and provisional biopharmaceutical classification Mol Pharm 2004 1 1 85 96 15832504
   PubMed Web of Science ®Google Scholar
• Takagi T Ramachandran C Bermejo M Yamashita S Yu LX Amidon GL A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Mol Pharm 2006 3 6 631 643 17140251
   PubMed Web of Science ®Google Scholar
• Bergström CAS Norinder U Luthman K Artursson P Molecular descriptors influencing melting point and their role in classification of solid drugs J Chem Inf Comput Sci 2003 43 4 1177 1185 12870909
   PubMedGoogle Scholar
• Preiss U Bulut S Krossing I In silico prediction of the melting points of ionic liquids from thermodynamic considerations: a case study on 67 salts with a melting point range of 337 degrees C J Phys Chem B 2010 114 34 11133 11140 20690695
   PubMed Web of Science ®Google Scholar
• Zhang Y Maginn EJ A comparison of methods for melting point calculation using molecular dynamics simulations J Chem Phys 2012 136 14 144116 22502510
   PubMed Web of Science ®Google Scholar
• Wu CY Benet LZ Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm Res 2005 22 1 11 23 15771225
   PubMed Web of Science ®Google Scholar
• Custodio JM Wu CY Benet LZ Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption Adv Drug Deliv Rev 2008 60 6 717 733 18199522
   PubMed Web of Science ®Google Scholar
• Benet LZ The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development J Pharm Sci 2013 102 1 34 42 23147500
   PubMed Web of Science ®Google Scholar
• Dahan A Beig A Ioffe–Dahan V Agbaria R Miller J The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane AAPS J 2013 15 2 347 353 23242514
   PubMed Web of Science ®Google Scholar
• Dahan A Miller JM The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs AAPS J 2012 14 2 244 251 22391790
   PubMed Web of Science ®Google Scholar
• Morgen M Bloom C Beyerinck R Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug Pharm Res 2012 29 2 427 440 21863477
   PubMed Web of Science ®Google Scholar
• Beig A Miller JM Dahan A Accounting for the solubility–permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption Eur J Pharm Biopharm 2012 81 2 386 391 22387337
   PubMed Web of Science ®Google Scholar
• Miller JM Beig A Krieg BJ The solubility–permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation Mol Pharm 2011 8 5 1848 1856 21800883
   PubMed Web of Science ®Google Scholar
• Dahan A Hoffman A Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intra-enterocyte processes in rats Pharm Res 2006 23 9 2165 2174 16902814
   PubMed Web of Science ®Google Scholar
• Dahan A Hoffman A The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats Eur J Pharm Biopharm 2007 67 1 96 105 17329087
   PubMed Web of Science ®Google Scholar
• Dahan A Hoffman A Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs J Control Release 2008 129 1 1 10 18499294
   PubMed Web of Science ®Google Scholar
• Koga K Takarada N Takada K Nano-sized water-in-oil-in-water emulsion enhances intestinal absorption of calcein, a high solubility and low permeability compound Eur J Pharm Biopharm 2010 74 2 223 232 19755156
   PubMed Web of Science ®Google Scholar
• Beig A Agbaria R Dahan A Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations PLoS One 2013 8 7 e68237 23874557
   PubMed Web of Science ®Google Scholar
• Beig A Miller JM Dahan A The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off Eur J Pharm Biopharm 2013 85 3 1293 1299 23770429
   PubMed Web of Science ®Google Scholar
• Dahan A Miller JM Hoffman A Amidon GE Amidon GL The solubility–permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone J Pharm Sci 2010 99 6 2739 2749 20039391
   PubMed Web of Science ®Google Scholar
• Miller JM Dahan A Gupta D Varghese S Amidon GL Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs J Control Release 2009 137 1 31 37 19264104
   PubMed Web of Science ®Google Scholar
• Sharma P Varma MV Chawla HP Panchagnula R In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies Farmaco 2005 60 11–12 874 883 16243320
   PubMedGoogle Scholar
• Sun J Dahan A Amidon GL Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach J Med Chem 2010 53 2 624 632 19957998
   PubMed Web of Science ®Google Scholar
• Gupta D Varghese Gupta S Dahan A Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue Mol Pharm 2013 10 2 512 522 23244438
   PubMed Web of Science ®Google Scholar
• Varghese Gupta S Gupta D Sun J Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach Mol Pharm 2011 8 6 2358 2367 21905667
   PubMed Web of Science ®Google Scholar
• Radwan A Amidon GL Langguth P Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity Biopharm Drug Dispos 2012 33 7 403 416 22782559
   PubMed Web of Science ®Google Scholar
• Dahan A Duvdevani R Shapiro I Elmann A Finkelstein E Hoffman A The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration J Control Release 2008 126 1 1 9 18082281
   PubMed Web of Science ®Google Scholar